Molecular Insight Pharmaceuticals, Inc. To Present Data on Four Oncology Candidates at Society of Nuclear Medicine 2008 Annual Meeting
Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) announced today that it will present study results on four of its oncology candidates at the 55th annual meeting of the Society of Nuclear Medicine (SNM). The meeting will take place June 14 -18, 2008 in New Orleans, LA. Presentations will include data on Azedra(TM) (Ultratrace(TM) 131I-MIBG), the company’s targeted radiotherapeutic candidate for the treatment of neuroendocrine tumors; Trofex(TM), its molecular imaging radiopharmaceutical candidate for the detection and monitoring of prostate cancer; Onalta(TM), a targeted radiotherapeutic complementary to Azedra that is in development for the treatment of neuroendocrine tumors such as carcinoid; and Solazed(TM), a targeted radiotherapeutic in development for the treatment of metastatic melanoma. The abstract and presentation details are as follows:
Abstract Title: Molecular targeting of melanoma with radiolabeled benzamides Authors: J. L. Joyal(1), S. M. Hillier(1), J. C. Marquis(1), J. Chen(1), M. Friebe(2), J. A. Barrett(1), J. F. Kronauge(1) and J. W. Babich(1); 1. Discovery Research, Molecular Insight Pharmaceuticals, Inc., Cambridge, Massachusetts and 2. Molecular Imaging Research, Bayer Healthcare, Berlin, Germany Reference #: 456331 Publication No.: 61 – Scientific Paper Session (oral) Session Info: Basic Science: Therapeutic Approaches Sunday, June 15 12:45 PM – 2:15 PM Room 225-226
Abstract Title: Comparative analysis of (111)In-edotreotide, (90)Y- edotreotide and (111)In-pentetreotide in vivo and in vitro Authors: J. C. Marquis(1), S. M. Hillier(1), T. Besanger(1), J. F. Kronauge(1), J. A. Barrett(1), T. L. Anderson(2), D. J. Irwin(2), J. P. Norenberg(2), J. L. Joyal1 and J. W. Babich(1); 1. Molecular Insight Pharmaceuticals, Inc., Cambridge, Massachusetts and 2. University of New Mexico Health Sciences Center, College of Pharmacy, Albuquerque, New Mexico Reference #: 461899 Publication No.: 63 – Scientific Paper Session (oral) Session Info: Basic Science: Therapeutic Approaches Sunday, June 15 12:45 PM – 2:15 PM Room 225-226
Abstract Title: A novel infusion method for therapeutic radiopharmaceuticals Authors: D. L. Yokell(1), S. C. Dragotakes(2), P. W. Gallagher(3), M. de la Guardia(1), J. F. Kronauge(1), J. P. Norenberg(4), N. A. Petry(5), J. A. Ponto(6) and J. W. Babich(1); 1. Molecular Insight Pharmaceuticals, Inc., Cambridge, Massachusetts; 2. Massachusetts General Hospital, Boston, Massachusetts; 3. Brigham and Women’s Hospital, Boston, Massachusetts; 4. University of New Mexico, Albuquerque, New Mexico; 5. Duke University Medical Center, Durham, North Carolina and 6. University of Iowa Hospitals and Clinics, Iowa City, Iowa Reference #: 461312 Publication No.: 1298 – Scientific Poster Session Poster Section: Radiopharmacy Posters Session Info: Meet the Author II Monday, June 16 3:15 PM – 4:00 PM Exhibit Hall B2
Abstract Title: The development of an SAR with small molecule inhibitors of prostate specific membrane antigen (PSMA) Authors: K. P. Maresca, S. M. Hillier, F. J. Femia, C. Barone, D. Keith, J. L. Joyal, C. N. Zimmerman, J. A. Barrett, W. C. Eckelman and J. W. Babich; Molecular Insight Pharmaceuticals, Inc., Cambridge, Massachusetts Reference #: 455192 Publication No.: 1236 – Scientific Poster Session Poster Section: New Chemistry-Oncology Posters Session Info: Meet the Author II Monday, June 16 3:15 PM – 4:00 PM Exhibit Hall B2
Abstract Title: Ongoing phase I evaluation of MTD, safety and efficacy of Iobenguane I 131 in malignant pheochromocytoma and paraganglioma (Pheo) Authors: R. Coleman(1), M. A. Morse(1), N. LaFrance(2), K. A. Kacena(2) and J. W. Babich(2); 1. Radiology, Duke University Medical Center, Durham, North Carolina and 2. Molecular Insight Pharmaceuticals, Inc., Cambridge, Massachusetts Reference #: 463712 Publication No.: 402 – Scientific Paper Session (oral) Session Info: TMI: Clinical Radionuclide Therapy Tuesday, June 17 9:45 AM – 11:15 AM Room 225-226
Abstract Title: ((123)I)-MIP-1095 for targeting prostate cancer via prostate specific membrane antigen (PSMA): A high specific activity radiosynthesis Authors: F. J. Femia, K. P. Maresca, S. M. Hillier, J. C. Marquis, E. Luss-Lusis, C. N. Zimmerman, J. L. Joyal, B. Abeysekera, J. F. Kronauge and J. W. Babich; Molecular Insight Pharmaceuticals, Inc., Cambridge, Massachusetts Reference #: 449940 Publication No.: 393 – Scientific Paper Session (oral) Session Info: New Chemistry-Oncology II: Small Molecules Tuesday, June 17 2:30 PM – 4:00 PM Room 215-216
Abstract Title: Small molecule PSMA inhibitors for targeted molecular imaging of prostate cancer Authors: S. M. Hillier(1), K. P. Maresca(1), F. J. Femia(1), C. N. Zimmerman(1), J. A. Barrett(1), C. A. Foss(2), W. C. Eckelman(1), M. G. Pomper(2), J. L. Joyal(1) and J. W. Babich(1); 1. Molecular Insight Pharmaceuticals, Inc., Cambridge, Massachusetts and 2. Johns Hopkins Medical Institutions, Baltimore, Maryland Reference #: 453735 Publication No.: 389 – Scientific Paper Session (oral) Session Info: New Chemistry-Oncology II: Small Molecules Tuesday, June 17 2:30 PM – 4:00 PM Room 215-216
Abstract Title: Determination of the ability of 111In Onalta (edotreotide) to be used as an imaging surrogate for the accurate prediction of 90Y Onalta radiation absorbed dose Authors: J. A. Barrett(1), T. Anderson(2), S. Hillier(1), D. Irwin(2), J. P. Norenberg(2), J. B. Stubbs(3), M. G. Stabin(3), J. L. Joyal(1), K. Kacena(1) and J. W. Babich(1); 1. research, Molecular Insight Pharmaceuticals, Inc., Cambridge, Massachusetts; 2. College of Pharmacy, University of New Mexico, Albuquerque, New Mexico and 3. Radiation Dosimetry Systems, Palo Alto, California Reference #: 456518 Publication No.: 1411 – Scientific Poster Session Poster Section: Therapy, Metrics & Intervention Posters Session Info: Meet the Author III Tuesday, June 17 4:30 PM – 5:15 PM Exhibit Hall B2
About Molecular Insight Pharmaceuticals, Inc.
Molecular Insight Pharmaceuticals (NASDAQ: MIPI) is a biopharmaceutical company specializing in the emerging field of molecular medicine, applying innovations in the identification and targeting of disease at the molecular level to improve healthcare for patients with life-threatening diseases. The company is focused on discovering, developing and commercializing innovative, molecular radiotherapeutics and molecular imaging pharmaceuticals with initial applications in the areas of oncology and cardiology. Its lead molecular radiotherapeutic product candidates, Azedra and Onalta, are being developed for detection and treatment of cancer. The company’s lead molecular imaging pharmaceutical product candidate, Zemiva, is being developed for the diagnosis of cardiac ischemia, or insufficient blood flow to the heart. In addition, the company has a growing pipeline of product candidates resulting from application of its proprietary platform technologies to new and existing compounds. Molecular Insight Pharmaceuticals is based in Cambridge, Massachusetts and its website address is: www.molecularinsight.com.
Forward-Looking Statements
Statements in this release that are not strictly historical in nature constitute “forward-looking statements.” Such statements include, but are not limited to, our anticipated completion date of mid-2008 for enrollment in the Zemiva planned pivotal registration trial, other listed expectations about meeting clinical milestones in 2008, as well as other statements regarding the development of Azedra(TM), Onalta(TM), Zemiva(TM) and our other product candidates. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results of Molecular Insight to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for product candidates; competition from other pharmaceutical or biotechnology companies; and the additional risks discussed in filings with the Securities and Exchange Commission. All forward-looking statements are qualified in their entirety by this cautionary statement, and Molecular Insight undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof.